Interpace Pancreas Test Reimbursement Code Changed
The new code is expected to streamline the reimbursement process and positively impact the way remittances are received from Medicare and commercial payors.
Interpace FY15 Revenues Rise on MDx Acquisitions
The company attributed increases to both its revenues and expenses to the 2014 acquisition of RedPath Integrated Pathology and two tests from Asuragen.
Interpace Announces Additional Job Cuts as Part of Restructuring
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
Interpace Receives Medicare Coverage for microRNA Thyroid Cancer Classifier
The test is used in conjunction with the firm's ThyGenX oncogene panel to assess fine needle aspiration samples from indeterminate thyroid nodules.
The firm performed a long-term, prospective study and noted that the test improved outcomes for patients and helped doctors monitor patients with benign disease.